DGAP-News: Alphaform AG: Preliminary figures for the first

DGAP-News: Alphaform AG / Key word(s): Half Year Results/Change in Forecast Alphaform AG: Preliminary figures for the first six months of 2012 23.07.2013 / 16:28 --------------------------------------------------------------------- Press release Preliminary figures for the first six months of 2013: Alphaform feels the economical break Forecast for the business year 2013 is adjusted downwards Revenue decreases by 10.5 % to EUR 12.6 million compared to previous year Group result within the first six months considerably deteriorated to EUR -1.1 million Feldkirchen, 23rd July 2013 - Alphaform AG, a specialist in 3D-printing and one of the leading companies in the production of orthopaedic implants and instruments, today announced a downwards adjusted forecast for the current business year. Due to cyclical customer retention and increasing price pressure the company decided to adjust downwards its previous revenue forecast for the business year from EUR 27 to 29 million to EUR 26.5 million. Earnings after taxes are expected to be slightly negative contrary to the previous forecast of EUR 0.8 million. The company emphasizes that the revised forecast solely reflects existing business and economic development. Speculative business opportunities due to new areas and technologies like 3D Printing or laser-sintered implants, which are strongly stressed by the company, were not considered in the forecast. Alphaform revenue decreased in the first six months of 2013 by 10.5 % to EUR 12.6 million compared to the same period of the previous year (first six months in 2012: EUR 14.1 million). Net result of the first six months declined from EUR 0.4 million in 2012 to EUR -1.1 million in 2013. In addition to the mentioned negative economic influences and price reductions hereby the non-recurring expenses for the extension of the 3D-printing sector as well as a more sustainable production is reflected. If only considering the second quarter, a clearly increasing order income since May can be registered, especially in the industrial 3D-printing sector. The Alphaform share registered a loss per share of EUR -0.20 per share within the first six months of 2013; in the first six months of 2012 this merit lay at a profit of EUR 0.07 per share. Retention concerning automotive manufacturers The 3D printing sector as well as additive manufacturing suffered from cyclically weak demands. The manufacture of prototypes for the automotive industry, which is still very important for Alphaform, clearly declined within the first four months of the year. Especially our main customers ordered more cautiously. However, since May the situation improved considerably and order income is even very satisfying since June. Altogether, the recessive business activity complicates the forecast concerning the further development. Within the past months, the demand on laser-sintered products was clearly increasing. In our opinion, this trend is firm, and therefore we started running an additional production unit in June. In the same time the whole additive manufacturing sector was restructured, its start-up costs of EUR 0.25 million were booked in the second quarter as well. Should the 3D-printing demand on customer side further increase, we will additionally extend our production capacity in order to cope with the customer demand in this sector. Furthermore we took steps to improve the production efficiency by optimized material usage and automated processes. Price decline within Medical Division Within the Alphaform Medical Division considerable market influences were perceptible, too. Temporarily, orders could only be recieved by giving considerable price reductions, which more than compensated our efficiency profits we still achieve. In the second quarter we though experienced a slight business recovery, which continues until now. We therefore are confident that the Medical Division will at least stay firm in the further course of the year. Our laser-sintering pilot-facility for 3D-printing of metal implants could have positive impacts in the near future. The development of our foreign subsidiaries in Scandinavia and Great Britain is positive. In the first six months of 2013 a slightly profitable growth of 2.0 % in all sections could be achieved. Key figures of the Alphaform Group <pre> In million EUR 2nd 2nd Cha- 1st 1st Cha- quarter quarter nge half half nge 2013 2012 in % 2013 2012 in % Revenues 6.041 7.329 -17.6 12.608 14,083 -10.5 EBITDA -0.636 0.615 -203.4 -0.288 1,161 -124.8 Operating result -0.945 0.289 -427.0 -0.892 0,508 -275.6 Earnings after taxes -1.031 0.235 -538.7 -1.067 0,387 -375.7 Earnings per share -0.19EUR 0.04EUR -575.0 -0.20EUR 0,07EUR -385.7 Equity as at 30th June 11.722 12,631 -8.3 Total assets as of 30th 20.263 20,485 -5.2 June Free cash equivalents as at 0.896 1,142 -45.1 30th of June (2012 as at 31st of Dec.) Employees in the Group as at 227 231 -1.7 30th of June </pre> For further informations concerning business development in the first six months of business year 2013 we refer to the Interim Report 2nd Quarter of the company, which will be released on 9th August 2013. About Alphaform Alphaform AG, based in Feldkirchen near Munich and founded in 1996, is a production company for complex components and products produced in small batches. Alphaform belongs to the European market leaders in 3D-printing for prototyping and to the production of series closer prototypes, particularly for the automotive and capital goods industries. The company has a leading position throughout Europe in manufacturing orthopaedic implants and instruments. The Alphaform share is listed in the Prime Standard Segment of the Frankfurt Stock Exchange (FWB) under the abbreviation ATF. The core competence of Alphaform lies in its extensive application know-how for processes and materials for the 3D-printing of complex prototypes, tools, individual components and small series made of plastics and metal. The company's activity is focused on the orthopaedic and medical technology, automotive, aviation and aerospace industries. The subsidiaries of Alphaform are located in Germany, Finland, Sweden and the UK. Contact: Dr. Thomas Vetter, CEO Tel.: +49 89 905002 21 ALPHAFORM AG Fax: +49 89 9050021021 Kapellenstra�e 10 e-mail: tvetter@alphaform.de 85622 Feldkirchen Internet: www.alphaform.de End of Corporate News --------------------------------------------------------------------- 23.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Alphaform AG Kapellenstra�e 10 85622 Feldkirchen Germany Phone: +49 (0)89 905002 - 0 Fax: +49 (0)89 905002 - 90 E-mail: ir@alphaform.de Internet: www.alphaform.de ISIN: DE0005487953 WKN: 548795 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 222544 23.07.2013